2 active not recruiting, 1 recruiting, 1 terminated, 1 unknown. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow IDH1 Gene Mutation: new trials by email Literature Review of IDH1 Gene Mutation trials Research Report on IDH1 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia Ivosidenib combined with venetoclax and azacitidine - Acute Myeloid Leukemia, IDH1 Gene Mutation | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 42 | 2025-06-01 | 2025-06-06 |
| AG-120 in People With IDH1 Mutant Chondrosarcoma AG-120 - Chondrosarcoma, Chondrosarcoma, Grade 2 | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 6 | 2020-03-04 | 2026-04-23 |
| BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas PARP Inhibitor BGB-290, Temozolomide (TMZ) - Glioblastoma, IDH1 Gene Mutation | Phase 1 | Active not recruiting | University of California, San Francisco | 78 | 2019-04-03 | 2026-03-13 |
| Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Busulfan, Cyclophosphamide, Fludarabine - Anemia, ASXL1 Gene Mutation | Phase 2 | Terminated | University of Utah | 6 | 2018-03-30 | 2022-05-05 |
| Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia Acute Myeloid Leukemia, IDH1 Gene Mutation | Unknown | Istituto Clinico Humanitas | 654 | 2016-01-01 | 2020-05-13 |
Leukemia, Myeloid, Acute (2) · Anemia (1) · Chondrosarcoma (1) · Glioblastoma (1) · Glioma (1) · Lymphoma, Follicular (1) · Multiple Myeloma (1) · Primary Myelofibrosis (1) · Thrombocytopenia (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Hemic and Lymphatic Diseases (4) · Hematologic Diseases (3) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Myeloid (2) · Lymphoproliferative Disorders (2) · Astrocytoma (1) · Blood Platelet Disorders (1) · Blood Protein Disorders (1) · Bone Marrow Diseases (1) · Cardiovascular Diseases (1) · Cytopenia (1)
Azacitidine (1) · Busulfan (1) · Cyclophosphamide (1) · Hematopoietic Stem Cell Transplantation (1) · Stem Cell Transplantation (1) · Temozolomide (1) · fludarabine (1) · ivosidenib (1) · pamiparib (1) · venetoclax (1)
Istituto Clinico Humanitas (1) · Memorial Sloan Kettering Cancer Center (1) · The First Affiliated Hospital of Soochow University (1) · University of California, San Francisco (1) · University of Utah (1)
United States (3) · China (1) · Italy (1)
Catherine Lee, MD (1) · Christoph Roellig (1) · Ciara M Kelly, MBBCh, BAO (1) · Francesc Sole, MD (1) · Joana Desterro (1) · Jorge Sierra (1) · Klaus Metzeler (1) · Lisa Pleyer (1) · Maria Teresa Voso (1) · Matteo Della Porta, MD (1) · Moritz Middeke (1) · Pau Montesinos (1) · Sabine Mueller, MD, PhD (1)
PMID 20142433, PMID 20171147, PMID 20421455, PMID 21079611, PMID 21130701, PMID 22453240, PMID 23393090, PMID 23558173, PMID 23634996, PMID 23641016, PMID 23645565, PMID 24030381, PMID 24935723, PMID 26016821, PMID 38446419